Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




- Framework agreement with Actelion Pharmaceuticals Ltd. signed
-  Actelion  receives   system  solutions  in   the  areas  of   gene
optimization, gene synthesis and plasmid preparation exclusively from
GENEART from now on
- The service portfolio of GENEART accelerates product development in
biotechnology when  compared  to conventional  methods  of  molecular
biology
-  DIN  EN  ISO  9001:2000  certification  guarantees  high   quality
standards for the development of pharmaceutical agents

Regensburg, July  7,  2009  -  GENEART  AG,  global  leader  in  Gene
Synthesis and specialist in the field of Synthetic Biology, announces
the signing of a framework agreement with the Swiss company  Actelion
Pharmaceuticals Ltd.  Within the  scope of  this agreement,  Actelion
will receive system solutions for DNA engineering & processing  (gene
optimization, gene  synthesis  and plasmid  preparation)  exclusively
from GENEART from now on. Further contract terms were not  disclosed.
The contract does not restrict GENEART in supplying service solutions
for other customers. The company, listed in the Swiss blue-chip index
SMI®, is  active in  research, development  and commercialization  of
innovative  biopharmaceutical  therapies.  The  drugs  developed  and
marketed by Actelion include Tracleer®  for instance - an  endothelin
receptor   antagonist   for   patients   with   pulmonary    arterial
hypertension.

"We are  delighted  that  we  have  been  able  to  convince  another
well-known company, Actelion, of the advantages of our technology for
the development of biopharmaceutical therapeutics. Gene  optimization
and gene synthesis offer many advantages over conventional methods in
molecular biology.  For  instance,  genes  can  be  tailored  to  the
respective customer project  by our  GeneOptimizer® software  without
any restrictions and  subsequently produced within  a few days.  This
not only shortens development times for biopharmaceuticals, but  also
increases the yield  and thus reduces  production and project  costs.
The fully DIN EN ISO 9001:2000 certified processes of GENEART and the
world-wide highest production capacities additionally ensure reliable
and quick  processing of  customer projects  with observance  of  the
required quality  standards  for the  development  of  pharmaceutical
agents", Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.


For further inquiries, please contact:

Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information:
This document  may contain  estimates, prognoses  and opinions  about
company plans and objectives,  products or services, future  results,
opinions about these results or opinions leading up to these results.
All  these  projections  into  the   future  are  subject  to   risk,
uncertainty and  unforeseeable  change  outside the  control  of  the
GENEART Group.  Many  factors  may  lead  to  actual  results,  which
considerably deviate from the given projections for these results.

About GENEART AG:
In 2000,  GENEART entered  the gene  synthesis market  and has  since
become the global  market leader. Today,  the company is  one of  the
leading specialists  in  the  Synthetic  Biology  field.  Experts  at
GENEART provide key technologies  for the development and  production
of new therapeutics  and vaccines. Customers  also take advantage  of
GENEART  services  to  customize  enzyme  attributes,  such  as   the
attributes of enzymes used as  detergent additives, and to  construct
bacteria, which produce complex  biopolymers or break down  polymers,
such as  synthetics, petroleum  components, etc.  Our production  and
service spectrum spans a wide range, from the production of synthetic
genes according to  DIN EN  ISO 9001:2000,  to the  creation of  gene
libraries in  the  combinatorial  biology,  to  the  development  and
production of DNA-based biologically active substances. GENEART AG in
Regensburg (Germany)  and the  subsidiaries GENEART  Inc. in  Toronto
(Canada) and GENEART Inc. in San Francisco (USA) employ more than 190
people. GENEART is listed on the German Stock Exchange.

About Actelion Pharmaceuticals Ltd.:
Actelion Pharmaceuticals Ltd. is a biopharmaceutical company with its
corporate headquarters  in Allschwil/Basel,  Switzerland.  Actelion's
first drug Tracleer®,  an orally available  dual endothelin  receptor
antagonist, has been  approved as  a therapy  for pulmonary  arterial
hypertension. Actelion markets Tracleer® through its own subsidiaries
in key markets worldwide, including the United States (based in South
San Francisco),  the European  Union,  Japan, Canada,  Australia  and
Switzerland. Actelion, founded in late  1997, is a leading player  in
innovative science related to the  endothelium - the single layer  of
cells separating every blood vessel from the blood stream. Actelion's
over  2,000  employees  focus  on  the  discovery,  development   and
marketing of innovative  drugs for significant  unmet medical  needs.
Actelion shares are traded on the SIX Swiss Exchange (ticker  symbol:
ATLN) as part of the Swiss blue-chip index SMI® (Swiss Market Index).

hugin.info/136633/R/1327235/312624.pdf


 
--- End of Message ---

Geneart AG
Josef-Engert-Str.11 Regensburg Germany

WKN: A0JJ4L; 
ISIN: DE000A0JJ4L4; 
Listed: Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Berlin, 

Open Market in Frankfurter Wertpapierbörse, Freiverkehr in Börse 
Stuttgart;